Latest Biotech News

Roche agreed to acquire PathAI for up to $1.05 billion to expand its digital pathology capabilities and accelerate AI adoption in companion diagnostics. The deal structure calls for a $750 million...

Pacific Biosciences cut the high end of its 2026 revenue guidance by $5 million after reporting flat Q1 revenue tied to softer instrument demand, particularly for its Vega platform, and continued...

Guardant Health reported Q1 2026 revenue of $301.7 million, up 48% year over year, and increased its full-year guidance to $1.30 billion to $1.32 billion. The ramp was driven by continued growth...

Natera increased its 2026 guidance after first-quarter 2026 revenue jumped 39% year over year, reflecting strength across its clinical oncology business and women’s health testing. Management said...

BillionToOne reported Q1 2026 revenue of $108.4 million, up 84% year over year, citing growth across prenatal clinical testing and related services. The company said it accessioned 189,000 tests...

Moonlight AI, a Swiss developer of diagnostic image-analysis software, raised $3.3 million in private financing to expand its dataset linking cytology images to genomic biomarkers. The company...

Odyssey Therapeutics priced an upsized initial public offering at $18 per share to raise about $304 million in gross proceeds, following a prior attempt to go public that was paused earlier. The...

Cellular Origins and Immatics expanded their manufacturing technology collaboration, agreeing to use Cellular Origins’ automated mobile robotic platform, Constellation, for parts of Immatics’ cell...

Bayer struck a deal to expand its ophthalmology pipeline by acquiring Perfuse Therapeutics for up to $2.45 billion. The purchase gives Bayer full rights to PER-001, a small-molecule endothelin...

Pierre Fabre and Atara Biotherapeutics won a significant pivot from the U.S. FDA on Ebvallo (tabelecleucel) after the agency’s earlier surprise rejection. The FDA agreed to reconsider approval...

Roche agreed to acquire PathAI in a deal potentially worth up to $1.05 billion, aiming to accelerate the rollout of AI-powered diagnostic tools within Roche Diagnostics. The acquisition includes a...

Imagenomix, an NYU Langone spinout developing AI-driven cancer diagnostics from standard histopathology images, raised $3.2 million in seed funding. The company said it uses AI to detect genetic...

Odyssey Therapeutics priced and launched its initial public offering, raising $279 million at $18 per share, plus an additional $25 million from a concurrent private stock sale at the same price....

A University of Virginia study reported mechanistic data in mice suggesting next-generation oral small-molecule GLP-1 receptor agonists suppress hedonic eating through reward circuits deeper in...

BillionToOne reported a surge in Q1 2026 revenue driven by increased prenatal and oncology-related clinical testing. The company posted $108.4 million in Q1 revenue, up 84% year over year, with...

Cellular Origins expanded its collaboration with Immatics to use Cellular Origins’ automated mobile robotic platform, Constellation, in parts of Immatics’ cell therapy manufacturing workflows. The...

Atara and Pierre Fabre’s Ebvallo resubmission plan follows the FDA’s decision to reconsider the regulatory evidence strategy after a second discussion with agency officials. The companies said the...

Roche’s PathAI acquisition follows a broader wave of investment in AI-enabled diagnostics, as the pharma giant seeks to scale digital pathology tools for precision oncology. PathAI’s platform...

The FDA has agreed to reconsider approval for Atara Biotherapeutics and Pierre Fabre Pharmaceuticals’ allogeneic T-cell therapy Ebvallo (tabelecleucel) after a surprise January rejection. The...

Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for about $4.1 billion in cash, adding three FDA-approved rare disease medicines to its portfolio and creating a direct entry into the...